The Evolving Modern Management of Brain Metastasis

被引：94

作者：

Fecci, Peter E. ^{[1
,2
]}

Champion, Cosette D. ^{[1
,2
]}

Hoj, Jacob ^{[3
]}

McKernan, Courtney M. ^{[3
]}

Goodwin, C. Rory ^{[1
,2
]}

Kirkpatrick, John P. ^{[1
,2
,4
]}

Anders, Carey K. ^{[5
]}

Pendergast, Ann Marie ^{[3
]}

Sampson, John H. ^{[1
,2
]}

机构：

[1] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC USA

[2] Duke Univ, Med Ctr, Duke Ctr Brain & Spinal Metastases, Durham, NC USA

[3] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC USA

[4] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA

[5] Duke Univ, Med Ctr, Duke Canc Inst, Div Med Oncol, Durham, NC USA

来源：

CLINICAL CANCER RESEARCH | 2019年 / 25卷 / 22期

关键词：

CELL LUNG-CANCER; NERVOUS-SYSTEM METASTASES; POSTOPERATIVE STEREOTACTIC RADIOSURGERY; LAPATINIB PLUS CAPECITABINE; BREAST-CANCER; OPEN-LABEL; SURGICAL RESECTION; RANDOMIZED-TRIAL; SINGLE METASTASES; RADIATION-THERAPY;

D O I：

10.1158/1078-0432.CCR-18-1624

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The incidence of brain metastases is increasing as cancer therapies improve and patients live longer, providing new challenges to the multidisciplinary teams that care for these patients. Brain metastatic cancer cells possess unique characteristics that allow them to penetrate the blood-brain barrier, colonize the brain parenchyma, and persist in the intracranial environment. In addition, brain metastases subvert the innate and adaptive immune system, permitting evasion of the antitumor immune response. Better understanding of the above mechanisms will allow for development and delivery of more effective therapies for brain metastases. In this review, we outline the molecular mechanisms underlying development, survival, and immunosuppression of brain metastases. We also discuss current and emerging treatment strategies, including surgery, radiation, disease-specific and mutation-targeted systemic therapy, and immunotherapy.

引用

页码：6570 / 6580

页数：11

共 105 条

[1] Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) [J].

Ahn, M. ;

Cho, B. C. ;

Siena, S. ;

Drilon, A. ;

De Braud, F. ;

Krebs, M. ;

John, T. ;

Karapetis, C. ;

Johnson, A. ;

Chow-Maneval, E. ;

Multani, P. ;

Doebele, R. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1783-S1783

[2] Stereotactic laser ablation as treatment for brain metastases that recur after stereotactic radiosurgery: a multiinstitutional experience [J].

Ali, Mir Amaan ;

Carroll, Kate T. ;

Rennert, Robert C. ;

Hamelin, Thomas ;

Chang, Leon ;

Lemkuil, Brian P. ;

Sharma, Mayur ;

Barnholtz-Sloan, Jill S. ;

Myers, Charlotte ;

Barnett, Gene H. ;

Smith, Kris ;

Mohammadi, Alireza M. ;

Sloan, Andrew E. ;

Chen, Clark C. .

NEUROSURGICAL FOCUS, 2016, 41 (04)

[3] Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial [J].

Andrews, DW ;

Scott, CB ;

Sperduto, PW ;

Flanders, AE ;

Gaspar, LE ;

Schell, MC ;

Werner-Wasik, M ;

Demas, W ;

Ryu, J ;

Bahary, JP ;

Souhami, L ;

Rotman, M ;

Mehta, MP ;

Curran, WJ .

LANCET, 2004, 363 (9422) :1665-1672

[4] Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases - A randomized controlled trial [J].

Aoyama, Hidefumi ;

Shirato, Hiroki ;

Tago, Masao ;

Nakagawa, Keiichi ;

Toyoda, Tatsuya ;

Hatano, Kazuo ;

Kenjyo, Masahiro ;

Oya, Natsuo ;

Hirota, Saeko ;

Shioura, Hiroki ;

Kunieda, Etsuo ;

Inomata, Taisuke ;

Hayakawa, Kazushige ;

Katoh, Norio ;

Kobashi, Gen .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2483-2491

[5]

ARBIT E, 1995, CANCER, V76, P765, DOI 10.1002/1097-0142(19950901)76:5<765::AID-CNCR2820760509>3.0.CO

[6]

2-E

[7] A New Treatment Paradigm: Neoadjuvant Radiosurgery Before Surgical Resection of Brain Metastases With Analysis of Local Tumor Recurrence [J].

Asher, Anthony L. ;

Burri, Stuart H. ;

Wiggins, Walter F. ;

Kelly, Renee P. ;

Boltes, Margaret O. ;

Mehrlich, Melissa ;

Norton, H. James ;

Fraser, Robert W. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (04) :899-906

[8] Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain [J].

Avraham, Hava Karsenty ;

Jiang, Shuxian ;

Fu, Yigong ;

Nakshatri, Harikrishna ;

Ovadia, Haim ;

Avraham, Shalom .

JOURNAL OF PATHOLOGY, 2014, 232 (03) :369-381

[9] Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study [J].

Bachelot, Thomas ;

Romieu, Gilles ;

Campone, Mario ;

Dieras, Veronique ;

Cropet, Claire ;

Dalenc, Florence ;

Jimenez, Marta ;

Le Rhun, Emilie ;

Pierga, Jean-Yves ;

Goncalves, Anthony ;

Leheurteur, Marianne ;

Domont, Julien ;

Gutierrez, Maya ;

Cure, Herve ;

Ferrero, Jean-Marc ;

Labbe-Devilliers, Catherine .

LANCET ONCOLOGY, 2013, 14 (01) :64-71

[10] SOD Therapeutics: Latest Insights into Their Structure-Activity Relationships and Impact on the Cellular Redox-Based Signaling Pathways [J].

Batinic-Haberle, Ines ;

Tovmasyan, Artak ;

Roberts, Emily R. H. ;

Vujaskovic, Zeljko ;

Leong, Kam W. ;

Spasojevic, Ivan .

ANTIOXIDANTS & REDOX SIGNALING, 2014, 20 (15) :2372-2415

← 1 2 3 4 5 6 7 8 9 10 →